Market Closed -
Other stock markets
|
Pre-market 07:00:22 am | |||
262.7 USD | -0.53% | 265.6 | +1.11% |
Apr. 17 | UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating | MT |
Apr. 16 | Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease | MT |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.